Mid-Day Market Update: Dow Tumbles 500 Points; Abeona Therapeutics Shares Plummet
Midway through trading Friday, the Dow traded down 1.39% to 35,398 while the NASDAQ fell 0.30% to 15,134.89. The S&P also fell, dropping 0.92% to 4,625.58.
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor.
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Genfit SA (NASDAQ: GNFT) rose 47.5% to $4.90 in pre-market trading. Ipsen and GENFIT reported an exclusive licensing agreement for Elafibranor.
SVB Leerink Downgrades Abeona Therapeutics to Market Perform, Lowers Price Target to $1
SVB Leerink analyst Mani Foroohar downgrades Abeona Therapeutics (NASDAQ:ABEO) from Outperform to Market Perform and lowers the price target from $5 to $1.
10 Biggest Price Target Changes For Monday
Citigroup cut Merck & Co., Inc. (NYSE: MRK) price target from $105 to $85. Merck shares fell 2% to $77.55 in pre-market trading.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Abeona Therapeutics To Present At Jefferies Gene Therapy/Editing Summit
Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies
Abeona Therapeutics Announces Clinical Data Presentations At Upcoming Scientific Congresses
Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021.